2026 ASCO Member Publications

Cancer center research at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026

Oral/Rapid Oral Abstract Sessions

Abstract titleIU authors; presenter names are boldedDate/timeAbstractSession/abstract link
Lung Cancer—Non-Small Cell Metastatic Nasser Hanna (chair and moderator)May 29
1 - 4 p.m. CDT		N/Ahttps://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17108
Medical Education and Professional Development: Rapid Oral Abstract SessionJennifer E. Schwartz (chair and moderator)May 29
2:45 - 4:15 p.m. CDT		N/Ahttps://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17114
First-line odronextamab (Odro) plus chemotherapy (CHOP) in diffuse large B-cell lymphoma (DLBCL): OLYMPIA-3 Part 1B results.Rita AssiMay 29
1 - 2:30 p.m. CDT		7009https://www.asco.org/abstracts-presentations/268033
First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.Lawrence H. EinhornMay 30
3 - 6 p.m. CDT		LBA5003https://www.asco.org/abstracts-presentations/260571
Outcomes of a feasibility and safety trial of tile-based radiation therapy with cesium-131 followed by external beam radiation therapy with concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma (NCT05342883).Angela RichardsonMay 31
4:30 - 6 p.m. CDT		2011https://www.asco.org/abstracts-presentations/259094
Impact of electronic patient-reported outcome measure (ePROM)–triggered, collaborative care (CC)–based symptom intervention on depression and anxiety in young adults (YAs) with cancer.Kurt KroenkeJune 1; 11:30 a.m. - 2:30 p.m. CDT12007https://www.asco.org/abstracts-presentations/258200
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ""Bright Spots and Blind Alleys in Small Cell Lung Cancer"Misty Shields, MD, PhD (discussant)June 1; 1:15 p.m. - 4:15 p.m. CDThttps://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17111

Education Sessions/Panels

Session titlePresenterDate/timeSession detailsSession link
JCO Workshop: The Ins and Outs of Medical Publishing—From Preparing Your Manuscript to Peer Review Presentation:  "Facing the Blank Page: How to Prepare Your Manuscript and Select the Right Journal in an Ever-Shifting Landscape"Kathy D. MillerMay 29
1 - 3:15 p.m. CDT		Workshophttps://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17194?presentation=257693
From Myelodysplastic Syndrome to Acute Myeloid Leukemia: Treatment-Related Myeloid Neoplasm Diagnosis and Therapeutic StrategiesRita Assi (chair and moderator)May 30
8 - 9 a.m. CDT		Case-Based Panelhttps://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17039
Highlights of the Year I: Highlights in Non-Small Cell Metastatic Lung CancerGreg DurmMay 31
8 - 9:15 a.m. CDT		Highlights of the Day Session: Special Sessionhttps://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17098?presentation=267988
Global Oncology: A Workforce Crisis—A Lancet Oncology CommissionPatrick J. Loehrer Sr.May 31
4:30 - 5:45 p.m. CDT		Education Sessionhttps://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17227
How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer "First-Line Therapy for Patients With Poor Risk Testicular CancerNabil Adra, MD (chair and presenter)June 1
1:15 - 2:30 p.m. CDT		Education Sessionhttps://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17036

Symposium

Abstract titleIU authors; presenter names are boldedDate/timeAbstract numberAbstract link
Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study. - Clinical Science SymposiumNabil AdraMay 30
8 - 9:30 a.m. CDT; Hall D2		4510https://www.asco.org/abstracts-presentations/260586

Poster Sessions

Abstract titleIU authors; presenter names are boldedDate/timeAbstract number, poster numberAbstract link
Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905.Nabil AdraMay 31
9 a.m. –  12 p.m CDT		Abstract #4613
Poster Bd #92		https://www.asco.org/abstracts-presentations/260709
Influence of TONSL on tumor suppressor function of RAD57 and resistance to CDK4/6 inhibitors in ER+ breast cancerHarikrishna NakshatriJune 1
1:30 - 4:30 p.m CDT		Abstract #1097
Poster Bd #211		https://www.asco.org/abstracts-presentations/261277/
Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).Bryan P. SchneiderMay 30
1:30 - 4:30 p.m CDT		Abstract #12117
Poster Bd #100		https://www.asco.org/abstracts-presentations/268251
EA1181: Accuracy of pre-surgery MRI to predict pathologic complete response after taxane, trastuzumab, and pertuzumab (THP) in HER2-positive breast cancer.Kathy D. MillerJune 1
1:30 - 4:30 p.m CDT		Abstract #603
Poster Bd #88		https://www.asco.org/abstracts-presentations/265816
Final results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated biliary tract cancer (NAPOLI-2).Anita TurkMay 30
9 a.m. –  12 p.m CDT		Abstract #4122
Poster Bd #105		https://www.asco.org/abstracts-presentations/264047
MUC5AC-driven transcriptional reprogramming for stratification of pancreatic ductal adenocarcinoma by immune suppression and stromal remodeling.Melissa FishelMay 30
9 a.m. –  12 p.m CDT		Abstract #4194
Poster Bd #177		https://www.asco.org/abstracts-presentations/267306
Relationships between clinical stage, pathological stage, and disease-free (DFS) survival in renal cell carcinoma as used to inform future neoadjuvant study design: ECOG-ACRIN EA8143 PROSPER analysis.Nabil AdraMay 31
9 a.m. –  12 p.m CDT		Abstract #4540
Poster Bd #19		https://www.asco.org/abstracts-presentations/262634
UTOPIA: A phase 3 trial of UGN-103, an intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.Hristos Z. KaimakliotisMay 31
9 a.m. –  12 p.m CDT		Abstract #4604
Poster Bd #83		https://www.asco.org/abstracts-presentations/262629
Integrated clinical and genomic analysis of mediastinal germ cell tumors (GCT) with somatic transformation (SM): A multi-institutional cohort study.Lawrence H. Einhorn, Nabil AdraMay 31
9 a.m. –  12 p.m CDT		Abstract #5029
Poster Bd #124		https://www.asco.org/abstracts-presentations/260794
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes.Huda SalmanJune 1
9 a.m. –  12 p.m CDT		Abstract #6592
Poster Bd #385		https://www.asco.org/abstracts-presentations/258802
Monalizumab plus durvalumab plus platinum-based chemotherapy for first-line treatment of extensive stage small-cell lung cancer: Early efficacy results from MOZART trial.Misty D. Shields, Shadia I. JalalMay 31
9 a.m. –  12 p.m CDT		Abstract #8098
Poster Bd #572		https://www.asco.org/abstracts-presentations/261385
Impact of lung cancer screening in patients diagnosed with small cell lung cancer.Paresh Kumar, Julian A. Marin-Acevedo
Nasser H. Hanna
Misty D. Shields		May 31
9 a.m. –  12 p.m CDT		Abstract #8102
Poster Bd #576		https://www.asco.org/abstracts-presentations/263838
Comparison by immunotherapy agent of real-world outcomes with chemoimmunotherapy in first-line extensive-stage small cell lung cancer.Paresh Kumar, Julian A. Marin-Acevedo, Misty D. ShieldsMay 31
9 a.m. –  12 p.m CDT		Abstract #8103
Poster Bd #577		https://www.asco.org/abstracts-presentations/263841
Demographics and outcomes of individuals with young-onset small cell lung cancer.Paresh Kumar, Julian A. Marin-Acevedo,
Misty D. Shields		May 31
9 a.m. –  12 p.m CDT		Abstract #8104
Poster Bd #578		https://www.asco.org/abstracts-presentations/265415
FUEL-IT Lung: Fasting to unleash and enhance lung cancer immunotherapy—A VA Lung Precision Oncology Program trial.Bharathi Muthusamy, Shadia I. JalalMay 31
9 a.m. –  12 p.m CDT		Abstract #TPS8666
Poster Bd #452b		https://www.asco.org/abstracts-presentations/266692
Clinical characteristics and risk factors of individuals ineligible for lung cancer screening at a tertiary care center.Julian A. Marin-Acevedo, ErinMarie Kimbrough, Peter Gunderman, Nawar Al Nasrallah,
Tim Lautenschlaeger,
Nasser H. Hanna		June 1
1:30 - 4:30 p.m CDT		Abstract #10529
Poster Bd #490		https://www.asco.org/abstracts-presentations/263881
Risk of immune-related adverse events from checkpoint inhibitors in cancer patients with autoimmune disease: An emulated target trial.Jiang Bian, Jingchuan GuoJune 1
9 a.m. –  12 p.m CDT		Abstract #11120
Poster Bd #103		https://www.asco.org/abstracts-presentations/259674/abstract
Race/ethnicity-stratified survival differences associated with psychotropic medication use in pancreatic cancer.Jiang BianMay 30
1:30 - 4:30 p.m CDT		Abstract #12072
Poster Bd #55		https://www.asco.org/abstracts-presentations/258436